Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil plus prednisone for newly diagnosed chronic graft-versus-host disease
NL-OMON58796Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic graft-versus-host disease (cGVHD) comparing Belumosudil + prednisone with Placebo + prednisone (2 arms). Primary endpoint: Event-Free Survival. Started Jul 2024; status: active, not recruiting.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NL-OMON58796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58796.